How does genetic polymorphism affect Alzheimer’s treatments?

This key study explores the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics (PK) of delta-9-tetrahydrocannabinol (THC) and its active metabolites in Alzheimer’s disease (AD) patients. Titled ‘A study on CYP2C9 polymorphism, in Puerto Rican Alzheimer’s patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol,’ it is accessible at the European Society of Medicine website.

Read More

What are the challenges in signal management in pharmacovigilance?

The conversation delves into the complexities of signal management in the PV landscape, highlighting recent advancements and the challenges faced under stringent regulatory requirements. Dr Buddha shares his expertise on how evolving technologies and methodologies are enhancing the detection, evaluation, and management of drug safety signals, ensuring patient safety and regulatory compliance. LL:​ The life sciences

Read More

CluePoints’ growth investment from EQT: What’s next?

CluePoints is a cloud-based software platform specializing in Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials. The platform is designed to streamline processes, improve data integrity, and ensure risk compliance, making clinical trials safer and more efficient. The investment by EQT, a firm with a strong track record in healthcare and technology,

Read More

EMA’s new clinical trials guideline

This guideline, which ensures regulatory compliance with the requirements of ICH GCP E6, came into effect on 9 September 2023. It introduced a new consolidated framework of standards for computerised systems and electronic data in clinical trials. It is a unique guideline in its thoroughness and extent on the matter. OSP had a conversation with Vesta

Read More

How will Thermo Fisher’s new EU Facility impact trials?

This expansion of Thermo Fisher’s clinical trial network in Europe will help foster global clinical trial innovation and provide biorepository storage solutions. Thermo Fisher Scientific Inc., a global leader in serving science, has launched this cutting-edge facility to support pharma and biopharma customers with tailored, end-to-end solutions throughout the clinical supply chain. This includes services

Read More

How does genetic polymorphism affect Alzheimer’s treatments?

This key study explores the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics (PK) of delta-9-tetrahydrocannabinol (THC) and its active metabolites in Alzheimer’s disease (AD) patients. Titled ‘A study on CYP2C9 polymorphism, in Puerto Rican Alzheimer’s patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol,’ it is accessible at the European Society of Medicine website.

Read More